Physician profile
Dawn Sims
NPI 1174912299
$3,338.77
in general payments reported to CMS, 2019-2025
11 companies · $866 in 2025
The $866 reported for 2025 was more than what 78% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $753 · 2022: $583 · 2023: $268 · 2024: $869 · 2025: $866.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,003.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,003.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $955.85 | 2021-2025 | Invega Sustenna, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $553.93 | 2021-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $458.03 | 2021-2025 | Austedo Xr, Austedo Xr |
| Neurocrine Biosciences, INC. | $449.68 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $404.73 | 2024-2025 | Caplyta |
| Abbvie INC. | $203.74 | 2021-2025 | |
| Axsome Therapeutics, INC. | $168.95 | 2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $52.72 | 2024 | Qelbree |
| Lundbeck LLC | $47.01 | 2024-2025 | Rexulti |
| Brainsway USA INC | $24.50 | 2023 | |
| Idorsia Pharmaceuticals US INC | $19.63 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dawn Sims listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.